TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$1.72 USD
+0.12 (7.50%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $1.73 +0.01 (0.58%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
TScan Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
TCRX 1.72 +0.12(7.50%)
Will TCRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TCRX
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
TCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
Other News for TCRX
Is TCRX setting up for a drop? Reversal New Lows Setup shows up after plummeting 6.98%
H.C. Wainwright Sticks to Their Buy Rating for TScan Therapeutics (TCRX)
Is TCRX set to rally? Hammer Candlestick shows up after gaining 1.78%
Bollinger Band Squeeze appears for TCRX after 3.98% move
Tracking Baker Brothers Portfolio - Q2 2025 Update